JP2024514830A5 - - Google Patents
Info
- Publication number
- JP2024514830A5 JP2024514830A5 JP2023561752A JP2023561752A JP2024514830A5 JP 2024514830 A5 JP2024514830 A5 JP 2024514830A5 JP 2023561752 A JP2023561752 A JP 2023561752A JP 2023561752 A JP2023561752 A JP 2023561752A JP 2024514830 A5 JP2024514830 A5 JP 2024514830A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- amino acid
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170976P | 2021-04-05 | 2021-04-05 | |
| US63/170,976 | 2021-04-05 | ||
| PCT/EP2022/059031 WO2022214499A2 (en) | 2021-04-05 | 2022-04-05 | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigenscross-reference to related applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514830A JP2024514830A (ja) | 2024-04-03 |
| JP2024514830A5 true JP2024514830A5 (enExample) | 2025-04-15 |
Family
ID=81307292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561752A Pending JP2024514830A (ja) | 2021-04-05 | 2022-04-05 | 新規腫瘍特異的抗原を使用する骨髄性障害および急性白血病の診断および処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240180963A1 (enExample) |
| EP (1) | EP4320154A2 (enExample) |
| JP (1) | JP2024514830A (enExample) |
| KR (1) | KR20240027578A (enExample) |
| CN (1) | CN117881700A (enExample) |
| AU (1) | AU2022255573A1 (enExample) |
| CA (1) | CA3216175A1 (enExample) |
| IL (1) | IL307498A (enExample) |
| MX (1) | MX2023011766A (enExample) |
| WO (1) | WO2022214499A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025511758A (ja) * | 2022-04-05 | 2025-04-16 | アルテイア サイエンス エッセ．エッレ．エッレ． | 新規腫瘍特異的抗原を標的とする骨髄性障害および急性白血病の処置 |
| WO2025113635A1 (zh) * | 2023-12-01 | 2025-06-05 | 上海祥耀生物科技有限责任公司 | 抗cd84抗体及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7361342B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2010035259A2 (en) * | 2008-09-23 | 2010-04-01 | Yeda Research And Development Co. Ltd. | Compositions and methods for diagnosing and treating b-cll |
| JP6847388B2 (ja) | 2013-03-15 | 2021-03-31 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 生物活性分子、そのコンジュゲート、及び治療用途 |
| WO2015121454A1 (en) * | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| US10828318B2 (en) * | 2016-01-06 | 2020-11-10 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
| EP3478324A1 (en) | 2016-07-01 | 2019-05-08 | GlaxoSmithKline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
| JP2022505921A (ja) * | 2018-10-26 | 2022-01-14 | カファ セラピューティクス リミテッド | Ｃｌｌ１を標的とする抗体およびその応用 |
-
2022
- 2022-04-05 US US18/285,850 patent/US20240180963A1/en active Pending
- 2022-04-05 IL IL307498A patent/IL307498A/en unknown
- 2022-04-05 CN CN202280040186.6A patent/CN117881700A/zh active Pending
- 2022-04-05 KR KR1020237038027A patent/KR20240027578A/ko active Pending
- 2022-04-05 AU AU2022255573A patent/AU2022255573A1/en active Pending
- 2022-04-05 MX MX2023011766A patent/MX2023011766A/es unknown
- 2022-04-05 CA CA3216175A patent/CA3216175A1/en active Pending
- 2022-04-05 JP JP2023561752A patent/JP2024514830A/ja active Pending
- 2022-04-05 WO PCT/EP2022/059031 patent/WO2022214499A2/en not_active Ceased
- 2022-04-05 EP EP22716261.7A patent/EP4320154A2/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3802598B1 (en) | Dll3/cd3 binding proteins for cancer treatment | |
| JP7438958B2 (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| CN119823267A (zh) | 特异性针对人类连接蛋白4的抗体 | |
| AU2018218753A1 (en) | Anti-GPRC5D antibody and molecule containing same | |
| CN113874399A (zh) | 抗ror1/抗cd3双特异性结合分子 | |
| CN113164780A (zh) | 抗lap抗体变体及其用途 | |
| JP2025511758A5 (enExample) | ||
| CN116829186A (zh) | 多特异性抗体及其用途 | |
| WO2023227062A1 (en) | Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| JP2024001073A5 (enExample) | ||
| KR20220082775A (ko) | 항-pd-1 항체 및 이의 용도 | |
| WO2023236891A1 (en) | Novel anti-lilrb4 antibodies and uses thereof | |
| AU2021253899A1 (en) | Antibodies to NKp46 and constructs thereof for treatment of cancers and infections | |
| JP2024514830A5 (enExample) | ||
| WO2024041315A1 (en) | Novel anti-lilrb2 antibodies and uses thereof | |
| KR102760955B1 (ko) | Gucy2c 결합 폴리펩타이드 및 그의 용도 | |
| JP7264337B2 (ja) | 抗ｂ７ｓ１ポリペプチドおよびその使用 | |
| EP3955925B1 (en) | Humanized anti-pd-l1 antibodies | |
| CN116836290B (zh) | 针对pd-l1和cd47的双特异性抗体、其制备方法及其用途 | |
| TWI889766B (zh) | 抗cd19抗體以及使用與製造其的方法 | |
| CN115368457A (zh) | 抗tigit抗体及其用途 | |
| KR20220082776A (ko) | 항-tigit 항체 및 이의 용도 | |
| WO2024196877A1 (en) | Rabbit monoclonal antibodies targeting acute myeloid leukemia antigens | |
| HK40121622A (en) | Dll3/cd3 binding proteins for the treatment of cancer | |
| WO2025041836A1 (ja) | 新規抗切断型変異ｃａｌｒ－ｃｄ３二重特性抗体及び医薬組成物 |